Search tips
Search criteria 


Logo of heartHeartVisit this articleSubmit a manuscriptReceive email alertsContact usBMJ
Heart. 2007 August; 93(8): 940–944.
Published online 2007 January 18. doi:  10.1136/hrt.2006.101949
PMCID: PMC1994422

Heart rate and microinflammation in men: a relevant atherothrombotic link


Objective and background

To explore the possibility that increased resting heart rate (HR) is associated with a microinflammatory response. Such an association could explain, at least in part, the recently described worse cardiovascular prognosis in individuals with increased HR.


Concentrations of fibrinogen and high‐sensitivity C‐reactive protein, as well as the absolute number of polymorphonuclear leucocytes, were analysed in a cohort of 4553 apparently healthy men and in those with atherothrombotic risk factors.


Following adjustment for age and body mass index, lipid profile and cardiovascular risk factors, a significant (p<0.001) difference was noted between individuals in the first quintile of HR ([less-than-or-eq, slant]58 beats/min) and those in the fifth quintile ([gt-or-equal, slanted]79 beats/min) regarding all the above‐mentioned inflammatory biomarkers, the respective mean values being 7.38 and 8.11 μmol/l, 1.12 and 1.61 mg/l, and 4.23 and 4.74×109/l.


Resting HR is associated with a microinflammatory response in apparently healthy men and in those with atherothrombotic risk factors. Sympathetic activation might be a common factor explaining such an association. If confirmed in additional studies, this association might be a relevant target for therapeutic manipulations.

Increased heart rate (HR) is an emerging new cardiovascular risk factor.1 In fact, it has been shown that high HR is prospectively related to the development of cardiovascular morbidity and mortality.2,3,4,5,6 The finding that even a single resting HR measurement has a predictive value5,7 has created a situation where every nurse or primary care physician can obtain a costless prognostic marker that is related to future cardiovascular morbidity and mortality. Moreover, this simple measurement can be a target for therapeutic interventions including drugs or lifestyle modification. Explaining the potential mechanisms that relate this measurement to future cardiovascular events might therefore be of relevance.

We herewith examined the inter‐relationships between a single resting HR measurement and the presence of a microinflammatory response in a group of apparently healthy individuals and in those with atherothrombotic risk factors. The significant correlation that we found might shed more light on the potential mechanisms that link HR with future cardiovascular events.


Study population

The present study was restricted to men, solely due to the microinflammatory changes that are observed during the menstrual cycle in women.8,9,10 We analysed the data that are currently available in the Tel Aviv Medical Center Inflammation Survey (TAMCIS), a registered data bank, Data Banks Registry, Ministry of Justice, State of Israel.11,12,13,14,15 This is a relatively large survey, in which we recruited apparently healthy individuals and those with atherothrombotic risk factors who were examined during their routine annual general health check‐up. All the individuals included in the present survey gave their written consent according to the instructions of the institutional ethics committee.


Patients attending the Tel Aviv Sourasky Medical Center (Tel Aviv, Israel) for a routine health examination between September 2002 and July 2006 were asked to participate in the TAMCIS. A total of 9289 subjects (5821 males, 3468 females) agreed to participate. Systematic examination of the reasons for participation yielded no effect of sociodemographic or biomedical variables. We excluded all female subjects from this analysis, owing to the effect of hormonal therapy (hormonal replacement therapy or oral contraceptives) and the effect of day of period on the inflammatory variables. From the 5821 men, an additional 947 subjects were later excluded from the analysis because of known inflammatory disease (arthritis, inflammatory bowel disease, psoriasis, etc), steroidal or non‐steroidal treatment (except for aspirin at a dose of [less-than-or-eq, slant]325 mg/dl), acute infection or invasive procedures (surgery, catheterisation, etc) during the last 6 months. An additional 181 subjects were excluded due to missing high‐sensitivity C‐reactive protein (hs‐CRP) concentrations, as well as the 1.5% of the highest hs‐CRP concentrations, and 140 subjects were excluded due to missing resting HR measurement. First, we analysed this cohort of 4553 individuals, and then excluded any individual with a history of proven vascular disease, including ischaemic heart disease, cerebrovascular accident or peripheral artery occlusive disease, as well as any individuals taking medications with a potential influence on HR, including nitrates, α blockers, β blockers, calcium channel blockers, antiarrhythmic drugs and digoxin, as well as any medications with a potential influence on inflammatory variables, including angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARB), HMG‐CoA reductase inhibitors and fibrates. We further excluded any individual with anaemia, defined as haemoglobin concentration below the lower normal limit according to our laboratory (which is 135 g/l), and any smoking individual, leaving 2878 individuals for the concise analysis. Finally, in order to test our hypothesis without any influence of proinflammatory conditions, we limited our cohort further to apparently healthy individuals, by excluding any individual with diabetes mellitus, hypertension or hyperlipidaemia, leaving 1879 individuals. Baseline resting HR was obtained manually at enrolment, with one radial pulse measurement during 60 s with the patient in a sitting position.

Definition of risk factors

Diabetes mellitus was defined as a blood glucose level of [gt-or-equal, slanted]7 mmol/l fasting or the use of insulin or oral hypoglycaemic medications. Hypertension was defined as a blood pressure of [gt-or-equal, slanted]140/90 mm Hg or the use of any antihypertensive medications, whereas hyperlipidaemia was defined as low‐density lipoprotein (LDL) cholesterol concentration or non‐high‐density lipoprotein (HDL) cholesterol concentrations, for individuals with triglyceride concentrations of [gt-or-equal, slanted]2.26 mmol/l, above the recommended goal according to the risk profile defined by the updated ATP III recommendations16 or the use of lipid‐lowering medications. Smokers were defined as those who smoke at least five cigarettes daily, whereas past smokers were defined as those who quit smoking for at least 30 days before examination.

Analytical methods

The white blood cell count (WBCC) and differential were determined by using the Coulter STKS (Beckman Coulter, Nyon, Switzerland) electronic cell analyser, quantitative fibrinogen level by the method of Clauss17 and a Sysmex 6000 (Sysmex Corporation, Hyaga, Japan) autoanalyzer, whereas the hs‐CRP level was determined by using a Behring BN II Nephelometer (DADE Behring, Marburg, Germany).18 The inter‐assay and intra‐assay variabilities did not exceed 3% for the hs‐CRP and 5% for the WBCC or fibrinogen assay.

Statistical analysis

All data were summarised and displayed as mean (standard deviation (SD)) for the continuous variables (age, body mass index(BMI), all the inflammation markers, etc), and as number of patients plus the percentage in each group for categorical variables (cardiovascular risk factors, etc). The crosstabs and descriptive procedures were used to produce frequencies of categorical variables and mean (SD) of continuous variables. The hs‐CRP and the triglyceride concentrations have non‐normal distribution; hence, we used a logarithmic transformation that converts it to a normal distribution for all statistical procedures such as corrections, analysis of variance (ANOVA) and analysis of covariance, and all the results for hs‐CRP or triglyceride concentrations were expressed as a back‐transformed geometrical mean (SD). The one‐way Kolmogorov–Smirnov test and the Q–Q plot were used to assess the distributions.

Pearson's partial correlations for confounding variables were performed to evaluate the association between resting HR and the different inflammatory variables. All correlations were carried out once bivariate, and then adjusted for age and BMI. To assess the gradual influence of resting HR, we divided our population into quintiles based on HR. For all continuous variables, the comparison between the different quintiles of HR was carried out using one‐way ANOVA, whereas for all categorical variables, it was carried out using The χ2 phi and Cramer's V statistics.

Estimated marginal means of inflammatory variables for the quintiles of resting HR were adjusted for age, waist, BMI, complete lipid profile, including LDL, HDL and triglycerides, diastolic and systolic blood pressure measurements, haemoglobin concentration, glucose concentration, alcohol consumption, sport intensity, medications, including nitrates, α blockers, β blockers, calcium channel blockers, ACE inhibitors, ARB, statins, fibrates, digoxin and antiarrhythmic drugs, and cardiovascular risk factors, including current and past smoking status, diabetes mellitus and family history of coronary heart disease, history of proven vascular disease including myocardial infarction, cerebrovascular accident or peripheral vascular disease, using analysis of covariance, under a general linear model. We further assessed the p value for trend, and the pairwise statistical significance between the quintiles of HR using the Bonferroni correction.

The level of significance used for all of the above analyses was two tailed, p<0.05. The SPSS statistical package, v 14.0, was used to perform all statistical evaluation.


We analysed a total of 4553 men at a mean (SD) age of 44.8 (11.2) years. Their characteristic age, BMI, blood pressure as well as alcohol consumption and sport intensity according to quintiles of resting HR and the percentages of individuals with different cardiovascular risk factors are presented in table 11,, whereas the respective percentages of individuals with different relevant medications are presented in table 22.. As expected, patients with lower HR exercise more, are leaner and overall healthier or use β blockers. A significant age‐ and BMI‐adjusted Pearson's partial correlation was noted between resting HR and the concentration of fibrinogen (r = 0.190, p<0.001), absolute polymorphonuclear count (r = 0.177, p<0.001) and hs‐CRP (r = 0.171, p<0.001).

Table thumbnail
Table 1 Mean (SD) of the different variables according to the quintiles of resting heart rate (HR), the one‐way ANOVA between the quintiles and the linear trend (upper part) and the number and percentage of the relevant cardiovascular ...
Table thumbnail
Table 2 Number and percentage of the relevant medications according to the quintiles of resting heart rate with the χ2 overall statistical significance between the quintiles

The estimated marginal mean (SE) of the different inflammatory biomarkers according to quintiles of resting HR after adjusting for age, BMI, waist, various medications, lipid profile and cardiovascular risk factors are reported in table 33.. It can be seen that the inflammatory biomarkers increase pari pasu with the resting HR increment. To minimise the effects of the different medications and conditions like anaemia and smoking on HR, we further excluded all individuals taking any medication with potential influence on HR or on inflammatory biomarkers, as well as any smoking patients and patients with anaemia, and performed the analysis again. This analysis demonstrates the same trend, as was in the entire cohort. Further exclusion of individuals with hypertension, diabetes mellitus or hyperlipidaemia, leaving just apparently healthy individuals, did not change the results significantly.

Table thumbnail
Table 3 Estimated marginal mean (SE) of the different inflammatory variables according to the quintiles of resting heart rate, with the one‐way ANOVA between the quintiles in the cohort


There are multiple lines of evidence to suggest a role for low‐grade, subclinical and smoldering internal inflammation (the so‐called microinflammation) in the pathogenesis of the atherothrombotic disease.19,20,21,22,23,24,25 Several recent studies have reported a relationship between this low‐grade inflammation and HR—an eventual predictor of future cardiovascular events.26,27 It is assumed that the sympathetic activation is the explanation, at least in part, for the association between increased HR and a heightened microinflammatory response.28

We have presently included three biomarkers that have an established association with cardiovascular morbidity and mortality, including the WBCC,29 quantitative fibrinogen30 as well as hs‐CRP.31 A main limitation of the leucocyte count in the present context is the possibility that both leucocyte count and HR can be the results of a transient surge of a sympathetic activity due to the stress of the examination itself. However, although leucocyte demargination during epinephrine release can increase within a couple of minutes, the time course for increment of hs‐CRP and especially fibrinogen are completely different.32 Therefore, the correlation with markers that are probably not influenced by a transient stressogenic stimulus is of special significance.

Although women were evaluated in the past,33 we did not include them in the present study. This was done because of potential confounders like oestrogen concentrations during the menstrual cycle34,35 or the influence of this cycle on the synthesis of inflammatory biomarkers.8,9,10 Therefore, relatively large cohorts of pre‐menopausal and post‐menopausal women are needed for a similar analysis in women.

The growing number of studies that relate a single resting HR measurement to future cardiovascular disease is of special interest due to the fact that this is almost a cost‐less marker. If confirmed in additional studies, the findings of the present study might be significant in that they shed some light on the possible associations between HR and the cardiovascular events. In fact, it is now conceivable that the inflammatory biomarkers are not necessarily innocent bystanders and might actually participate in the progression of the disease. This is true for both the white blood cells36 and the C‐reactive protein,37 as well as clottable fibrinogen.38 Therefore, the association of HR with these biomarkers might be relevant for the potential usefulness of HR as a predictor of cardiovascular diseases. In addition, therapeutic implications in terms of reducing both HR and inflammatory biomarkers by using β blockers might be of interest.39,40

Finally, it should be pointed that there is growing evidence to suggest an association between the autonomous nervous system and the inflammatory response. In fact, it has been shown that vagus nerve stimulation attenuates the LPS‐induced increases in plasma and splenic concentrations of proinflammatory cytokines, including TNF‐α and IL‐6.41 Electrical stimulation of the efferent vagus nerve reduced the release of TNF‐α in rats,42,43 an effect that appeared to be mediated by an effect of acetylcholine on α7 cholinergic receptors or macrophages.44 Electrical vagus nerve stimulation also inhibited the acute inflammatory response to acute hypovolaemic shock,45 splanchnic artery occlusion shock46 and intestinal inflammation during experimentally induced ileus.47 In addition, stimulation of the α7 cholinergic receptors attenuated systemic inflammation in mice with abdominal sepsis,48 reduced cytokine release in peritonitis,49 diminished the severity of experimental pancreatitis50 and suppressed endothelial cell activation during the localised Shwartzman reaction.51 Thus, one could suggest that individuals with increased vagal tone might present a less intense baseline inflammatory profile. It is tempting to assume that these vagotonic individuals also present a reduced heart rate, thus providing at least a partial explanation to our present observation.


Resting HR is associated with a microinflammatory response in apparently healthy men and in those with atherothrombotic risk factors. Sympathetic or vagal activation might be a common denominator that explains such an association.41,42,43,44,45,46,47,48,49,50,51,52 If confirmed in additional studies, this association might be a relevant target for therapeutic manipulations.


ACE - angiotensin converting enzyme

ARB - angiotensin II receptor blockers

BMI - body mass index

HDL - high density lipoprotein

HR - heart rate

hs‐CRP - high‐sensitivity C‐reactive protein

LDL - low density lipoprotein

TAMCIS - Tel Aviv Medical Center Inflammation Survey

WBCC - white blood cell count


Competing interests: None declared.


1. Palatini P. Heart rate: a strong predictor of mortality in subjects with coronary artery disease. Eur Heart J 2005. 26943–945.945 [PubMed]
2. Benetos A, Rudnichi A, Thomas F. et al Influence of heart rate on mortality in a French population: role of age, gender, and blood pressure. Hypertension 1999. 3344–52.52 [PubMed]
3. Menotti A, Mulder I, Nissinen A. et al Prevalence of morbidity and multimorbidity in elderly male populations and their impact on 10‐year all‐cause mortality: The FINE study (Finland, Italy, Netherlands, Elderly). J Clin Epidemiol 2001. 54680–686.686 [PubMed]
4. Palatini P, Thijs L, Staessen J A. et al Predictive value of clinic and ambulatory heart rate for mortality in elderly subjects with systolic hypertension. Arch Intern Med 2002. 1622313–2321.2321 [PubMed]
5. Palatini P, Casiglia E, Julius S. et al High heart rate: a risk factor for cardiovascular death in elderly men. Arch Intern Med 1999. 159585–592.592 [PubMed]
6. Disegni E, Goldbourt U, Reicher‐Reiss H. et al The predictive value of admission heart rate on mortality in patients with acute myocardial infarction. SPRINT Study Group. Secondary Prevention Reinfarction Israeli Nifedipine Trial. J Clin Epidemiol 1995. 481197–1205.1205 [PubMed]
7. Diaz A, Bourassa M G, Guertin M C. et al Long‐term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J 2005. 26967–974.974 [PubMed]
8. Giuliani A, Mitterhammer H, Burda A. et al Polymorphonuclear leukocyte function during the menstrual cycle and during controlled ovarian hyperstimulation. Fertil Steril 2004. 821711–1713.1713 [PubMed]
9. Feuring M, Christ M, Roell A. et al Alterations in platelet function during the ovarian cycle. Blood Coagul Fibrinol 2002. 13443–447.447
10. Blum C A, Muller B, Huber P. et al Low‐grade inflammation and estimates of insulin resistance during the menstrual cycle in lean and overweight women. J Clin Endocrinol Metab 2005. 903230–3235.3235 [PubMed]
11. Rogowski O, Shapira I, Zimran A. et al Automated system to detect low‐grade underlying inflammatory profile: Gaucher disease as a model. Blood Cells Mol Dis 2005. 3426–29.29 [PubMed]
12. Berliner S, Shapira I, Toker S. et al Benign hereditary leukopenia–neutropenia does not result from lack of low grade inflammation. A new look in the era of microinflammation. Blood Cells Mol Dis 2005. 34135–140.140 [PubMed]
13. Rogowski O, Toker S, Shapira I. et al Values of high sensitivity C‐reactive protein in each month of the year in apparently healthy individuals. Am J Cardiol 2005. 95152–155.155 [PubMed]
14. Rogowski O, Vered Y, Shapira I. et al Introducing the wide range C‐reactive protein (wr‐CRP) into clinical use for the detection of microinflammation. Clin Chim Acta 2005. 358151–158.158 [PubMed]
15. Berliner S, Rogowski O, Aharonov S. et al Erythrocyte adhesiveness/aggregation. A novel biomarker for the detection of low grade internal inflammation in individuals with atherothrombotic risk factors and proven vascular disease. Am Heart J 2005. 149260–267.267 [PubMed]
16. National Cholesterol Education Program (NCEP) Expert Panel Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001. 2852486–2497.2497 [PubMed]
17. Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol Basel 1957. 17237–246.246 [PubMed]
18. Rifai N, Tracy R P, Ridker P M. Clinical efficacy of an automated high‐sensitivity C‐reactive protein assay. Clin Chem 1999. 452136–2141.2141 [PubMed]
19. Viles‐Gonzalez J F, Fuster V, Badimon J J. Atherothrombosis: a widespread disease with unpredictable and life‐threatening consequences. Eur Heart J 2004. 251197–1207.1207 [PubMed]
20. Hansson G K. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005. 3521685–1695.1695 [PubMed]
21. Ridker P M. Cardiology patient page. C‐reactive protein: a simple test to help predict risk of heart attack and stroke, Circulation 2003. 108e81–e85.e85 [PubMed]
22. Biasucci L M. CDC/AHA workshop on markers of inflammation and cardiovascular disease: application to clinical and public health practice: clinical use of inflammatory markers in patients with cardiovascular diseases: a background paper. Circulation 2004. 110e560–e567.e567 [PubMed]
23. Libby P, Ridker P M, Maseri A. Inflammation and atherosclerosis. Circulation 2002. 1051135–1143.1143 [PubMed]
24. Ridker P M. On evolutionary biology, inflammation, infection, and the causes of atherosclerosis. Circulation 2002. 1052–4.4 [PubMed]
25. Ross R. Atherosclerosis‐‐an inflammatory disease. N Engl J Med 1999. 340115–126.126 [PubMed]
26. Sajadieh A, Nielsen O W, Rasmussen V. et al Increased heart rate and reduced heart‐rate variability are associated with subclinical inflammation in middle‐aged and elderly subjects with no apparent heart disease. Eur Heart J 2004. 25363–370.370 [PubMed]
27. Kazumi T, Kawaguchi A, Hirano T. et al C‐reactive protein in young, apparently healthy men: associations with serum leptin, QTc interval, and high‐density lipoprotein‐cholesterol. Metabolism 2003. 521113–1116.1116 [PubMed]
28. Lombardi F. Sympathetic activation and sub‐clinical inflammation: a new combination to identify high risk subjects. Eur Heart J 2004. 25359–360.360 [PubMed]
29. Coller B S. Leukocytosis and ischemic vascular disease morbidity and mortality: is it time to intervene? Arterioscler Thromb Vasc Biol 2005. 25658–670.670 [PubMed]
30. Maresca G, Di Blasio A, Marchioli R. et al Measuring plasma fibrinogen to predict stroke and myocardial infarction: an update. Arterioscler Thromb Vasc Biol 1999. 191368–1377.1377 [PubMed]
31. Libby P, Ridker P M. Inflammation and atherosclerosis: role of C‐reactive protein in risk assessment. Am J Med 2004. 1169S–16S.16S [PubMed]
32. Gabay C, Kushner I. Acute‐phase proteins and other systemic responses to inflammation. N Engl J Med 1999. 11448–454.454 [PubMed]
33. Chang M, Havlik R J, Corti M C. et al Relation of heart rate at rest and mortality in the Women's Health and Aging Study. Am J Cardiol 2003. 921294–1299.1299 [PubMed]
34. Kaya D, Cevrioglu S, Onrat E. et al Single dose nasal 17beta‐estradiol administration reduces sympathovagal balance to the heart in postmenopausal women. J Obstet Gynaecol Res 2003. 29406–411.411 [PubMed]
35. Carnethon M R, Anthony M S, Cascio W E. et al Prospective association between hormone replacement therapy, heart rate, and heart rate variability. The atherosclerosis risk in communities study. J Clin Epidemiol 2003. 56565–571.571 [PubMed]
36. Madjid M, Awan I, Willerson J T. et al Leukocyte count and coronary heart disease: implications for risk assessment. J Am Coll Cardiol 2004. 441945–1956.1956 [PubMed]
37. Labarrere C A, Zaloga G P. C‐reactive protein: from innocent bystander to pivotal mediator of atherosclerosis. Am J Med 2004. 117499–507.507 [PubMed]
38. Danesh J, Collins R, Peto R. et al Haematocrit, viscosity, erythrocyte sedimentation rate: meta‐analyses of prospective studies of coronary heart disease. Eur Heart J 2000. 21515–520.520 [PubMed]
39. Tatli E, Kurum T. A controlled study of the effects of carvedilol on clinical events, left ventricular function and proinflammatory cytokines levels in patients with dilated cardiomyopathy. Can J Cardiol 2005. 21344–348.348 [PubMed]
40. Yang S P, Ho L J, Cheng S M. et al Carvedilol differentially regulates cytokine production from activated human peripheral blood mononuclear cells. Cardiovasc Drugs Ther 2004. 18183–188.188 [PubMed]
41. van Westerloo D J, Giebelen I A, Meijers J C. et al Vagus nerve stimulation inhibits activation of coagulation and fibrinolysis during endotoxemia in rats. J Thromb Haemost 2006. 41997–2002.2002 [PubMed]
42. Borovikova L V, Ivanova S, Zhang M. et al Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature 2000. 405458–462.462 [PubMed]
43. Bernik T R, Friedman S G, Ochani M. et al Pharmacological stimulation of the cholinergic antiinflammatory pathway. J Exp Med 2002. 195781–788.788 [PMC free article] [PubMed]
44. Wang H, Yu M, Ochani M. et al Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature 2003. 421384–388.388 [PubMed]
45. Guarini S, Altavilla D, Cainazzo M M. et al Efferent vagal fibre stimulation blunts nuclear factor‐kappaB activation and protects against hypovolemic hemorrhagic shock. Circulation 2003. 1071189–1194.1194 [PubMed]
46. Altavilla D, Guarini S, Bitto A. et al Activation of the cholinergic anti‐inflammatory pathway reduces NF‐kappab activation, blunts TNF‐alpha production, and protects against splanchic artery occlusion shock. Shock 2006. 25500–506.506 [PubMed]
47. de Jonge W J, van der Zanden E P, The F O. et al Stimulation of the vagus nerve attenuates macrophage activation by activating the Jak2‐STAT3 signaling pathway. Nat Immunol 2005. 6844–851.851 [PubMed]
48. Wang H, Liao H, Ochani M. et al Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis. Nat Med 2004. 101216–1221.1221 [PubMed]
49. van Westerloo D J, Giebelen I A, Florquin S. et al The cholinergic anti‐inflammatory pathway regulates the host response during septic peritonitis. J Infect Dis 2005. 1912138–2148.2148 [PubMed]
50. van Westerloo D J, Giebelen I A, Florquin S. et al The vagus nerve and nicotinic receptors modulate experimental pancreatitis severity in mice. Gastroenterology 2006. 1301822–1830.1830 [PubMed]
51. Saeed R W, Varma S, Peng‐Nemeroff T. et al Cholinergic stimulation blocks endothelial cell activation and leukocyte recruitment during inflammation. J Exp Med 2005. 2011113–1123.1123 [PMC free article] [PubMed]
52. Tracey K J. The inflammatory reflex. Nature 2002. 420853–859.859 [PubMed]

Articles from Heart are provided here courtesy of BMJ Publishing Group